Hainan Shuangcheng Pharmaceuticals Co., Ltd. (SHE:002693)

Market Cap	3.14B
Revenue (ttm)	168.12M
Net Income (ttm)	-79.60M
Shares Out	414.69M
EPS (ttm)	-0.19
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	9,434,200
Average Volume	15,486,042
Open	7.59
Previous Close	7.58
Day's Range	7.50 - 7.63
52-Week Range	4.00 - 40.98
Beta	0.34
RSI	48.39
Earnings Date	Jul 31, 2025

About SHE:002693

Hainan Shuangcheng Pharmaceuticals Co., Ltd. provides peptide, lyophilized, oncology, oral dosage, and other injection cartridge pharmaceutical products worldwide. The company offers thymalfasin, thymapentin, bortezmib, paclitaxel, somatostatin, pantoprazole, epifibatide, bivalirudin, liraglutide, and exenatide and sodium ferulate for injections, as well as vitamin B6. Hainan Shuangcheng Pharmaceuticals Co., Ltd. was founded in 2000 and is based in Haikou, the People’s Republic of China.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2000
• Employees: 605
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 002693

Financial Performance

In 2024, SHE:002693's revenue was 174.21 million, a decrease of -26.16% compared to the previous year's 235.93 million. Losses were -78.30 million, 54.3% more than in 2023.